A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer
出版年份 2022 全文链接
标题
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer
作者
关键词
-
出版物
Future Oncology
Volume -, Issue -, Pages -
出版商
Future Medicine Ltd
发表日期
2022-05-25
DOI
10.2217/fon-2022-0310
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
- (2021) Erica L Mayer et al. LANCET ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States
- (2021) Qianyi Zhang et al. HEALTH SERVICES RESEARCH
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
- (2021) Elizabeth M. Salvo et al. BREAST
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
- (2021) N. Harbeck et al. ANNALS OF ONCOLOGY
- Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update
- (2021) Sharon H. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
- (2021) Kevin Kalinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Why Test for Proportional Hazards?
- (2020) Mats J. Stensrud et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
- (2020) Antonio C. Wolff JOURNAL OF CLINICAL ONCOLOGY
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibitors for HR+HER2− early stage breast cancer — when to escalate treatment?
- (2020) Giuseppe Curigliano Nature Reviews Clinical Oncology
- Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients
- (2020) Camille Moreau-Bachelard et al. Cancers
- CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
- (2020) Serena Di Cosimo et al. BREAST
- Liquid biopsy and minimal residual disease — latest advances and implications for cure
- (2019) Klaus Pantel et al. Nature Reviews Clinical Oncology
- Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015
- (2019) Robin Stuart-Harris et al. BREAST
- Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer
- (2018) Armando E. Giuliano et al. ANNALS OF SURGICAL ONCOLOGY
- Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence
- (2018) Takeshi Murata et al. Breast Journal
- Differences in Breast Cancer Survival by Molecular Subtypes in the United States
- (2018) Nadia Howlader et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Development and Validation of a High-Quality Composite Real-World Mortality Endpoint
- (2018) Melissa D. Curtis et al. HEALTH SERVICES RESEARCH
- Ipsilateral Breast Tumor Reappearance and Contralateral Breast Cancer after Primary Breast Cancer Treatment: A Comprehensive Retrospective Study of 15,168 Patients
- (2018) Giovanni Corso et al. ONCOLOGY
- Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women
- (2018) Tae In Yoon et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
- (2018) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy
- (2017) Fangbin Song et al. OncoTargets and Therapy
- Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations
- (2017) Nikita Wright et al. PLoS One
- Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1–2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy
- (2016) Shih-Fan Lai et al. ANNALS OF SURGICAL ONCOLOGY
- Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
- (2016) Marco Colleoni et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years
- (2016) Chiao-En Wu et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- The relationship between local recurrence and death in early-stage breast cancer
- (2015) Victoria Sopik et al. BREAST CANCER RESEARCH AND TREATMENT
- 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
- (2015) Christian Jackisch et al. Breast Care
- Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy
- (2015) S Baulies et al. BRITISH JOURNAL OF CANCER
- Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer
- (2015) M. Dowsett et al. CLINICAL CANCER RESEARCH
- Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer
- (2015) A. Kümmel et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Hazard of Recurrence among Women after Primary Breast Cancer Treatment--A 10-Year Follow-up Using Data from SEER-Medicare
- (2012) L. Cheng et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer
- (2010) Carine A Bellera et al. BMC Medical Research Methodology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More